US Patent 12103971 HIV specific binding molecules
Patent 12103971 was granted and assigned to Immunocore on October, 2024 by the United States Patent and Trademark Office.
All edits
US Patent 12103971 HIV specific binding molecules
Specific binding molecules, including T cell receptors (TCRs), which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17 are presented. TCRs of the present invention comprise non-natural mutations within the alpha and/or beta variable domains relative to a native TCR. The specific binding molecules of the invention have improved stability and/or yield and yet unexpectedly retain the advantageous properties of the specific binding molecules from which they are derived. Such specific binding molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.
Find more entities like US Patent 12103971 HIV specific binding molecules
